Finance

Lists
RNAC:NASDAQ
Cartesian Therapeutics Inc
$6.92
-1.35%
(-0.095) 1D
Nov 10, 1:35:37 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RNAC...
Open
$6.92
High
$7.28
Low
$6.90
Mkt. cap
211.23M
Avg. vol.
143.56K
Volume
41.38K
52-wk high
$11.00
52-wk low
$5.60
EPS
-$4.94
Beta
0.74
Shares outstanding
30.50M
No. of employees
75
Open
$6.92
High
$7.28
Low
$6.90
Mkt. cap
211.23M
Avg. vol.
143.56K
Volume
41.38K
52-wk high
$11.00
52-wk low
$5.60
EPS
-$4.94
Beta
0.74
Shares outstanding
30.50M
No. of employees
75
News stories
From web sources and news partners
About Cartesian Therapeutics Inc
CEO-
Employees75
Founded2007
HeadquartersFrederick, Maryland, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to RNAC in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for RNAC in the last 3 months.
Highest
Current $6.92
$44.00 (+535.38%)
Average
$36.75 (+430.69%)
Lowest
$25.00 (+261.01%)
Analyst
Recommendation
Action
Price target
Projected
Date
Martin Fan
Wedbush
Buy
Reiterated
$38.00
+448.7%
11/06/2026
Julian Harrison
BTIG
Buy
Maintained
$44.00
+535.4%
11/05/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+261%
11/06/2026
Gil Blum
Needham
Buy
Maintained
$40.00
+477.6%
09/29/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$40.00
+477.6%
08/11/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Reiterated
$16.00
+131%
08/06/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/06/2026
Unknown Analyst
Wedbush
Buy
Maintained
$38.00
+448.7%
06/10/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
05/27/2026
Matthew Biegler
Oppenheimer
Hold
Reiterated
-
-
03/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
947.00K
78.00K
-
-
Cost of goods sold
14.69M
19.46M
20.43M
15.62M
Cost of revenue
14.69M
19.46M
20.43M
15.62M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.20M
7.11M
8.72M
9.38M
Operating expense
8.20M
7.11M
8.72M
9.38M
Total operating expenses
22.89M
26.58M
29.16M
25.00M
Operating income
-21.94M
-26.50M
-29.16M
-25.00M
Other non operating income
702.00K
91.00K
-4.53M
3.62M
EBT including unusual items
-101.77M
-39.18M
15.77M
-11.47M
EBT excluding unusual items
-19.97M
-25.38M
-33.43M
-22.17M
Income tax expense
-9.19M
-
-
-
Effective tax rate
9.03%
-
-
-
Other operating expenses
-
-
-
-
Net income
-92.58M
-39.18M
15.77M
-11.47M
Net profit margin
-9,775.71%
-50,233.33%
-
-
Earnings per share
-2.71
-0.95
-0.96
-0.85
Interest and investment income
1.27M
1.03M
1.10M
1.20M
Interest expense
-
-
-852.00K
-1.99M
Net interest expenses
1.27M
1.03M
251.00K
-789.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.33M
-25.88M
-28.38M
-24.22M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps